Exhibit 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all additional amendments thereto) with respect to the ordinary shares of China Biologic Products Holdings, Inc. and further agree that this joint filing agreement (this “Agreement”) shall be included as an Exhibit to such joint filing. Each person further agrees as follows:

1. Each person executing this Agreement is responsible for the timely filing of such Schedule 13D and any subsequent amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but no person executing this Agreement is responsible for the completeness or accuracy of the information concerning any other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

2. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which, taken together, shall constitute one and the same instrument.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of April 8, 2020.

2019B CAYMAN LIMITED
By:	/s/ Rikizo Matsukawa
	Name:	Rikizo Matsukawa
	Title:	Director
CITIC Capital China Partners IV, L.P.
By: CCP IV GP LTD., its General Partner
By:	/s/ Chan Kai Kong
	Name:	Chan Kai Kong
	Title:	Director
CCP IV GP LTD.
By:	/s/ Chan Kai Kong
	Name:	Chan Kai Kong
	Title:	Director
CITIC CAPITAL PARTNERS LIMITED
By:	/s/ Chan Kai Kong
	Name:	Chan Kai Kong
	Title:	Director
CITIC CAPITAL HOLDINGS LIMITED
By:	/s/ Yichen Zhang
	Name:	Yichen Zhang
	Title:	Director

[Signature page to Schedule 13D Joint Filing Agreement]